Summary
JOIN PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €569,132 and a net result of €41,311. Equity is growing by about 2.9% per year across the filed financial years. Its solvency ranks better than 48% of 6,570 sector peers (NACE 64, financial year 2025). The company has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
30-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
05-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial
Highest result from 2018 to 2025net €55,419 ▲6.3%
Net result €55,419, the highest in the series.
31-12
Financial
Equity above €500,000equity €508,241 ▲10.1%
A profit in every financial year since 2018 builds equity to €508,241.
05-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
30-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
28-07
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
03-07
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
08-07
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
24-07
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
20-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.